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Surface active substances are widely used in medicine, among 
them the drugs capable of adsorption in efficient concentrations at 
various interface points. The relationship between the pharmacolo-
gical action of a ntiarrhythmic drugs and their surface activity and 
influence on the lipid-containing interfaces (bimolecular layers of 
phosphatidylcholine) have been studied. It has been revealed that 
diphisopronyle (diethylaminopropyl ether a-isopropyloxydiphenyl-
acetic acid, hydrochloride) , fubromegane (1-methyl-3-diethylamino-
propyl ether 5-bromofurane-2-carboxylic acid, iodomethylate), me-
thamicile (~-diethylaminopropyl ether benzyl acid, hydrochloride), 
propranolole (l-isopropylamino-3 (oxynaphtyl-1)--propanol-2, hydro-
chloride), chinidine (chinidine sulphate), novocainamide (~-diethyl­
aminoethyl-amid p-aminobenzoic acid, hydrochloride) , novocaine 
(~-diethylaminoethyl ether p-aminobenzoic acid, hydrochloride), xy-
locaine (N,N-diethylamino-2,6-dimethylacethanilide, hydrochloride), 
trimecaine (N,N-diethylamino-2,4,6-trimethylacethanilide, hydro-
chloride) possess surface activity. Parallelism between the physio-
logical action and interfacial activity of antiarrhythmic drugs has 
been established. Antiarrhythmics increase the electric conductance 
of lecithine bilayers. There exists a symbate dependence between 
the effect of drugs on the permeability of a bimolecular lecithin 
membra ne and . their pharmacological activity. These results are 
essential a) for understanding the mode of action of antiarrhythmic 
agents and b) discovering new drugs which possess the required 
properties. 
INTRODUCTION 
The progress of modern molecular pharmacology and surface chemistry 
makes it necessary to interpret in a new way many problems related to the 
investigation of the interaction of drugs and receptors. Physico-chemical and 
biological processes at the interfaces of the cellular structures and liquid 
disperse systems of the organism, which are determined by the surface active 
properties of drug molecules and the macromolecules of a living substrate 
referred to as receptor, may be considered as surface phenomena in the 
organism. 
Many drugs possess the adsorption ability on the interfaces in certain 
concentrations necessary for pharmacological action. The mechanism of action 
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of physiologically active substances is characterized by the intrinsic unity of 
two factors which, as it was stressed by P. A. Rehbinder, directly denote the 
nature of surface activity and form the basis for the use of surface active 
substances. These are: a) adsorption of surface active substances, i.e. the ability 
of the given molecules to concentrate at a certain interface in amounts, which 
are by far greater than their bulk concentrations; b) spontaneity of the 
adsorption process which is predetermined thermodynamically by the excess 
of free energy at the initial interface. However, the extent to which the ad-
sorption takes place may be limited by kinetic factors (mass transfer, dif-
fusion)1,2. 
The significance of the surface phenomena of the physiological active 
agents was first stated as early as 1927--19291 by P. A. Rehbinder. At present 
these investigations are still of essen t ial importance since it is impossible to 
represent the interaction. of a comparatively small molecule of a drug with 
a macromolecule of an organism if the phenomena w hich occur in the interfaces 
are not characterized. 
Formerly it was revealed that physical colloidal and chemical properties 
are of great importance for the mechanism of action of neurotropic drugs 
(anaesthetics, analgesics, antihistamines and curare-like agents)3-15• Special 
attention was paid to the elucidation of the role of surface phenomena.3,s,11 ,13,H 
In earlier studiesrn- rn, a supposition was voiced that the interaction of 
drugs with the membranes is of great importance for the realization of the 
antiarrhythmic effect. For example it is known that antiarrh ythmic action of 
B-blocking agents is connected with the »membrane-depressant« effect. There 
is even evidence of a correlation between the »membrane-depressant« influence 
of B-blockers and their effective antiarrhythmic doses (observed in patients)18 . 
At the same time, the role of surface phenomena in the mechanism of anti-
arrhythmic action is not clear yet . We thought it reasonable to study the role 
of surface phenomena in the mode of action of antiarrhythmic drugs. For this 
purpose the relationship between the pharmacological effect of various anti-
arrhythmic drugs and their surface activity and influence on the lipid-
containing interfaces: bimolecular layers of phosphatidylcholine, has been 
studied. 
MATERIALS AND METHODS 
The chemical structure of the antiarrhythmic drugs is given in Figure 1. The 
following compounds have been used: diphisoprohyle (diethylaminopropyl ether 
a-isopropyloxydiphenylacetic acid, hydrochloride)21, fubromegane (1-methyl-3-diethyl-
aminopropyl ether 5-bromofuran-2-carboxylic acid, iodomethylate)25 , methamicile 
(~-diethylaminopropyl ether benzylic acid, hydrochloride)2\ propranolole (l-isopropyl-
amino-3 (oxynaphthyl-1)-propanol-2, hydrochloride)25, chinidine (chinidine sulfate)25, 
novocainamide (~-diethylaminoethylamide p-aminobenzoic acid, hydrochloride)20 
novocaine (~-diethylaminoethyl ether p-aminobenzoic acid, hydrochloride)2°, xylocaine 
(N,N-diethylamino-2,6-dimethylacetanilide, hydrochloride)25, trimecaine (N,N-diethyl-
amino-2,4,6-trimethylacetanilide, hydrochloride) 2''· 
Investigations of surface active properties of antiarrhythmic drugs have been 
carried out in accordance with the method described previously in detail1 · ~. 
Surface activity of aqueous solutions of drugs has been studied at the air 
interface, interfaces of benzene and benzene solutions of nerve-tissue lipoproteins. 
Surface tension, a has, been measured by the method of maximum bubble (or drop) 
pressure using the P . A. Rehbinder apparatus. The measurements of a as a function 
of the concentration of each compound were always carried out at (20 ± 0.1) oc, in 
the equilibrium state, with pH being 7.0. Selection of the time interval required for 
the formation of an equilibrium adsorption layer was essential. Two series of 
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Figure 1. Antiarrhythmics formulae 
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determinations were carried out; during the first series of measurements the surface 
tension was determined immediately after the formation of the interface and during 
the second series - the surface tension was measured 30 min, 1 hour and 2 hours 
after the interface had been formed. The minimum speed at which the value of 
surface tension (a) remains practically constant was determined with the help of 
a - r plot (r is the bubble formation time). The results of these investigations have 
shown that the constant value of surface tension (a) is obtained rather rapidly. 
Therefore, a at the interface air-aqueous phase was determined at novel surfaces; at 
the interface formed by the aqueous phase with benzene and benzene solutions of 
nerve-tissue lipoproteins surface tension was measured after 2 hours. During all the 
experiments the maximum time of bubble formation was assumed equal to 4 to 5 
minutes. 
Preliminary measurements have shown that: 
a { (1 /15) mol dm-3 phosphate-buffer / air at 20 °c } = 72.7 mN m-1 
a {(1/15) mol dm-3 phosphate-buffer / benzene solutions} = 35.0 mN m-1 
a {(1/15) mol dm-3 phosphate-buffer / benzene solutions of nerve-tissue lipoproteins} 
= 21.14 mN m-1 
Each drug was investigated in eight concentrations. The mean value out of ten a 
measurements was assumed to be valid. The accuracy of a measurements is 0.1 mN m-1. 
The bilayer phosphatidylcholine membrane was used as a model of a biological 
membrane. It was formed by P. Mueller et al. method19 . 2°/o Solution of egg lecithin 
in n-heptane was used to form the bilayer. The identification of egg lecithin with 
the sample of synthetic lecithin20 was carried out by thin layer chromatography, IK 
spectra and optical rotation dispersion. On both sides of the lipid membrane a 
solution containing 0.25 mol sucrose, 5 mmol KC!, 5 mmol tris HCl (pH= 7.0 ; 
t = 30 °C) was present. Membrane resistance was measured by a circuit comprised 
of voltage supply, calibrated resistors, electrometer, and recording instrument 
KCII-4. Voltage of 50 mV was supplied to the membrane by means of two silver-
-chloride electrodes. Electric conductance of bimolecular lipid membranes was 
measured by comparison of voltage drop at the standard resistance and the mem-
brane resistance. Resistance of the membranes was (0.8 ± 0.02) X 101 Q 3 • 
In the experiments on urethane chloralose, anaesthetized cats experimental 
arrhythmia was evoked by threshold electric stimulation of heart auricles and 
ventricles for 10 s (1.5 v, 1 ms, 1 imps/s, continuous series). Mean effective dose (ED50) 
of drugs, preventing arrhythmia was determined. The ability of compounds to induce 
conduction anaesthesia was investigated on frogs by the Turke method. The concen-
tration of a compound at which the reflex of jerking balk of the leg disappeared 
for 5 min was assumed to be the minimum anaesthetic concentration. Surface 
anaesthesia was investigated on the cornea of a rabbit's eye by the Rengier method. 
The Rengier index was calculated to determine the anaesthetic activity of the drug. 
RESULTS 
It has been demonstrated that the antiarrhythmic compounds are surface 
active in concentrations from 2 · 10-3 mmol kg-1 to 1 · 10-2 mol kg-1 at all 
studied interfaces. With regard to their increasing surface activity at the 
air/solution interface the drugs may be arranged as follows: novocainamide < 
< chinidine < fubromegane < propranolole < methamicile < diphisopronyle. 
Novocaine, xylocaine and trimecaine are surface-active in greater concentrat-
ions ranging from 2 · 10-2 to 1 · 10- 1 mol (Figure 2) . 
P. A. Rehbinder showed that the compounds, which are surface inactive 
under the conditions of normal measurements at the air - aqueous solution 
interface, may appear to be capable of considerable adsorption at the interfaces 
of organism or of water-lipophile medium type models. These investigations 
brought about correct conceptions on the significance of surface activity in 
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Figure 2. Surface tension of antiarrhythmic solutions in 1/15 molar phosphate buffer , rr, as a 
function of molal concentration, c; (pH = 7.0 ; t = (20 ± 0.1•) C). 
a - for novocainamide (1), chinidine (3), fubromegane (4), propranolole (5), methamicile (8) , 
diphisopronyle (9); 
b - for novocaine (2) , xylocaine (6) and trimecaine (7) . 
Each curve point is a result of ten measurements of surface tension. 
the publication of these papers, a number of propositions of I. Traube himself 
and his followers22•2s as well as the significance of the specificity of phases 
which form the interface were determined. This specificity is important for the 
determination of the relationship between the pharmacological action and 
interfacial activity of drugs. 
Thus, it is impossible to limit modern studies on surface activity of phy-
siologically active compounds by mere measurements at the air/solution inter-
face. Surface-active properties should be determined on models which are as 
close to physiological conditions as possible. 
As a model we used the determination of interfacial activity of antiarr-
hythmic drugs at the antiarrhythmic solutions/benzene solutions of nerve-tissue 
lipoproteins interface. 
It has been shown that antiarrhythmics possess high interfacial activity 
(Figure 3). The order of antiarrhythmic drugs at the interface of benzene 
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Figure 3. Interfacial tension of antiarrhythmic solutions in 1/15 molar phosphate buffer at the 
boundary with benzene solutions of nerve-tissue lipoproteins 0-1,2 as a f u nction of molal con-
centration, c; pH = 7.0; t = (20 ± 0.1•) C). 
a - for novocainamide (1), propanolole (2), chinidine (3), fubromegane (4), methamicile (5), 
diphisopronyle (6); 
b - for novocaine (7), xylocaine (8) a nd trimecaine (9). 
Each curve point is a result of ten measurements of interfacial tension. 
solutions of nerve-tissue lipoproteins is as follows: novocainamide < propra-
nolole < chinidine < fubromegane < methamicile < diphisopronyle. This suc-
cession does not completely correspond to the one at the air-solution interface, 
which confirms the above-mentioned conception on the significance of the 
specificity of phases. Absolute surface activity of antiarrhythmic drugs at the 
air/solution interface, interfaces of benzene and benzene solutions of nerve-tis-
sue lipoproteins is different and this is quite natural. The influence of chemical 
structure of substances at the interface between lipid and water phases is less 
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evident as compared to the air-solution interface. This is seemingly connected 
with the identical conformational transformation (within the given range of 
concentrations) during the formation of the complicated adsorption layer 
which is formed by 'a lipoproteid complex together with the substance being 
studied. Comparison of the aiitiarrhythmic effect of the drugs to their surface 
and interfacial activity showed that there exists an interrelationship between 
these properties (Figure 4). The revealed interrelationship is more pronounced 
when comparing the antiarrhythmic action to the interfacial activity, than 
when comparing the pharmacological effect to the surface activity, which is 
quite normal as the first model is closer to physiological conditions. Comparing 
of surface and interfacial activity of antiarrhythmic drugs and their local 
anaesthetic action (conduction anaesthesia) has shown that these characteristics 
are also interrelated: highly active antiarrhythmic drugs have pronounced 
surface-active properties and iµduce conduction anaesthesia in lowest con-
centrations (Figure 4). These results correlate well with the data presented 
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Figure 4. Surface tension (0'1), interfacial tension (0"1.2) [at the concentration 1 · 10· 2 mmol kg··1 ; 
pH = 7.0; t = 20 'CJ, antiarrhythmic (ED50 and anaesthetic activity (MAC) of novocainamide (1), 
chinidine (2), fubromegane (3), propranolole (4), methamicile (5), diphisopronyle (6). /',. - ""': 
D - 0"1,2; 0 - EDoo; • - MAC. 
above as to the relationship between the local anaesthetic effect of drugs 
belonging to different chemical classes and their surface and especially inter-
facial activity (Figure 5). 
It is known that the influence of substances on monomolecular and 
bimolecular layers is closely connected with their surface activity. For example, 
it has been revealed that the monolayer of nerve-tissue lipids can serve as a 
model for the nerve axonal membrane during the investigation of local 
anaesthetics mode of action11• These open up broad possibilities in the organism 
for the formation of extremely thin adsorption layers of surface active sub-
stances both on the surface of living cells and on the various interior surfaces 
of cells. The living cells display spontaneous properties of surface-active lipids, 
specifically phospholipids, directed as bimolecular layers or membranes. The 
role of lipid component of the membrane in the mechanism of drug action may 
be estimated during the investigation of conductivity of artificial lipid mem-
branes at various concentrations of the drugs24 • 
For this purpose the influence of compounds, which have antiarrhythmic 
activity (diphisopronyle, trimecaine, novocainamid) on the properties of the 
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Figure 5. Correlation of local anaesthetic effect (unbroken line) and the surface activity (dashed 
line) of trimecaine (I) and xylocaine (II) 
1 - anaesthetic effect (Regnier index) 
2 - surface activity of aqueous solutions drugs at the interfaces of benzene solutions of 
nerve tissue lipoproteins (pH ~ 7.0; t ~ 20 oq. 
bilayer phospholipid membrane, has been investigated. The measurements of 
surface activity at different interface have been taken into consideration when 
selecting the agent concentrations. Diphisopronyle has been studied in the 
following concentrations: 0.05 mmol kg-1 ; 0.1 mmol kg-1 ; 0.2 mmol kg-1 ; 0.3 mmol 
kg-1 ; 0.4 mmol kg-1 ; 0.5 mmol kg-1. Trimecaine and novocainamid has been 
studied in the following concentrations: 0.25 mmol kg-1 ; 0.5 mmol kg-1 ; 0.75 mmol 
kg-1 ; 1.0 mmol kg-1 ; 1.25 mmol kg-1 ; 1.5 mmol kg-1. Two series of experiments 
were carried out. In the first series of tests, an attempt was made to investigate 
the influence of antiarrhythmic drugs on the electric conductivity and stability 
of the membrane under the conditions of introducing the drugs in the buffer 
solution from one side of the membrane. In the second series of tests the drugs 
were introduced from both sides of the membrane. The membrane becomes 
highly unstable if antiarrhythmic drugs are introduced into the buffer solution 
from one side of the membrane. It is supposed that antiarrhythmics by inter-
acting with the lecithin membrane upset the symmetry of its layers, which 
leads to the alteration of resistance and upsets the integrity of the membrane: 
The introduction of drugs from both sides of the membrane ensures its 
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stability. All further investigations were carried out under conditions of intro-
ducing antiarrhythmic drugs from both sides of the lecithin membrane. 
It has been demonstrated that diphisopronyle, trimecaine and novocainamid 
change the electric conductivity of the membrane. The reduction of m embrane 
electric resistance depends directly on the concentration of agents. 
Diphisopronyle in the concentration from 0.05 mmol kg-1 up to 0.5 mmol kg-1 
concentrations (pH = 7.0 ; t = 30 °C) causes considerable, by a factor of 102 , 
reduction of bimolecular membrane resistance. The influence of trimecaine on 
th e permeability of the bilayer lipid m embrane is less pronounced. The 
reduction of the mebrane resistance is obser ved at higher 0.5 to 10.0 mmol kg-1) 
concentrations of the drug. Novocainamid in higher concentrations up to 1 to 
1.5 mmol kg-1, reduces the membrane resistance insignifican t ly, only by 2 to 3 
times (Figure 6). In the course of the investigation of the kinetics of change, 
0.1 03 0.5 
c/(mmol kg-1 ) 
a -tor 1,2 
b-for 3 
Figure 6. Effect of antiarrhythmic drugs (in various concentrations, c) on the electric resistance 
(R) of bimolecular lecithin membrane; pH = 7.0; t = 30 oc. 
a - for novocainamide (1) and t r imecaine (2); 
b - for diphisopronyle (3). 
the membrane electric resistance revealed the following. Once the antiarrhyth-
mic drugs (Diphisopronyl in dose 0.2 mmol kg-1, trimecaine and novocainamide 
in dose 1 mmol kg-1) are introduced into the buffer solution which surrounds 
the membrane, the resistance remains unchanged; in 10 to 12 minutes the 
resistance changes abruptly. It is supposed that prior to the registration of the 
influence of the molecules on the electric conductivity of the membrane, 
a certain critical number of molecules should be adsorbed at the surface of the 
membrane and penetrate into it. 
The influence of the studied drugs on the permeability of the membrane 
is correlated with their antiarrhythmic activity: ED50 diphisopronyle = 3 · 10-3 
mol kg-1, trimecaine = 12 · 10-3 mol kg-1, novocainamide = 2 · 10-2 mol kg-1. 
This comparison may lead to the conclusion on the interrelationship between 
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the antiarrhythmic effect of drugs and their influence on the b ilayer lecithin 
membrane. The most active antiarrhythmic drugs have considerable affinity 
for the molecules of lecithin. This may be explained by their pronounced 
surface-active and lipophilic properties, as well as by the role of the chosen 
phospholipid in the formation of the antiarrhythmics receptor. Apparently the 
bilayers of phosphatidylcholine may serve as a model of receptors during the 
investigation of action of antiarrhythmic drugs. These results are essential for 
understanding the mode of action of antiarrhythmics on the receptor. 
Thus, the investigation of surface phenomena gives the information on the 
interaction of drug molecules (specifically antiarrhythmics) with macromolecules 
of receptors, i . e. on the primary pharmacological reaction. In addition to that 
the behaviour of the antiarrhythmics at the interfaces, which depends on their 
structure and on their colloido-chemical properties, makes it possible to pass 
a judgment on the probable structure and physico-chemical basis of receptor 
functions. Besides being of obvious theoretical significance this field of mo-
lecular pharmacology is of great practical importance since the revealed 
patterns can be used in the discovery of new drugs which possess the required 
properties. 
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SAZETAK 
Povrsinska aktivnost i mehanizam djelovanja antiaritmika 
V. V. Zakusov, N. T. Pryanishnikova i V. M. Samvelyan 
Istrazivana je uloga povrsinskih efekata na djelovanje antiaritmika: novokain-
amida, kinidina, fubromegana , propranolola, metamicila, difizopronila, novokaina, ksi-
lokaina i trimekaina, odnosno veza izmedu farmakoloskih efekata tih spojeva i nji-
hove povr5inske aktivnosti te utjecaja na medufaze koje sadrfavaju lipide (bimole-
kularne slojeve fosfatidilkolina) . Usporedba antiaritmickog efekta kao i lokalnoga-
anestetskog djelovanja s povrsinskom i medufaznom aktivnosti ovih lijekova poka-
zala je da postoji meduodnos ovih svojstava. Utjecaj spojeva na dvoslojnu fosfoli-
pidsku membranu tj. povrsinsku aktivnost, elektricnu vodljivost (otpor) i propusnost 
membrane, upucuje na zakljueak o meduodnosu antiaritmickog efekta ljekova i nji-
hovog utjecaja na dvoslojnu lecitinsku membranu i ulozi koristenog fosfolipida u 
sastavu antiaritmickog receptora. 
Istice se znacenje ovih rezultata za razumijevanje djelovanja antiaritmika na 
receptoru, tj. primarne farmakoloske reakcije. 
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